Resumen Introducción: Los niños infectados por el virus de la inmunodeficiencia humana (VIH) tienen mayor riesgo de presentar infecciones, incluyendo hepatitis por virus A (VHA). La vacuna inactivada contra el VHA es inmunógena en el huésped inmunocompetente. No hay estudios suficientes sobre el tiempo de seroprotección en niños infectados por el VIH. Método: Estudio de cohorte, analítico. Se incluyeron niños con infección por VIH-1 que recibieron la vacuna inactivada contra el VHA (dos dosis). Se les tomaron muestras sanguíneas para medición de anticuerpos, una 28 días después de la segunda dosis y otra 7 años después del esquema de vacunación. Se obtuvo información de carga viral, categoría inmunológica, peso y talla, y respuesta al tratamiento antirretroviral desde el diagnóstico hasta la última valoración. Resultados: Se incluyeron 19 pacientes con una edad media de 12.6 años (± 2.29). El 58% fueron del sexo masculino. El 80% de los pacientes presentaron anticuerpos immunoglobulin G (IgG) contra el VHA protectores a los 7 años de la vacunación. La concentración de anticuerpos se encontró entre 13 y 80 mUI/ml (mediana: 80 mUI/ml). El 52% mostraron algún grado de inmunosupresión. No existe relación estadísticamente significativa entre la presencia de seroprotección y la carga viral, la falla al tratamiento, la categoría inmunológica ni la desnutrición. Doce pacientes presentaron falla al tratamiento antirretroviral; en el 33% de ellos los anticuerpos no ofrecían seroprotección satisfactoria. Conclusiones: A 7 años posvacunación, el 80% de los niños con VIH mantienen títulos de seroprotección frente al VHA.

Abstract Background: HIV-infected children have a higher risk of presenting infections, including the hepatitis A virus (HAV). The inactivated HAV vaccine is immunogenic in immunocompetent hosts; however, there are insufficient studies on the duration of seroprotection in HIV-infected children. Methods: An analytical cohort study was conducted. HIV-1-infected children who received the inactivated HAV vaccine (2 doses) were included. Blood samples were taken for antibody measurement, the first one 28 days after the second dose and another 7 years after the vaccination schedule. Information on viral load, immunological category, weight, height, and response to antiretroviral treatment from diagnosis to the last assessment was obtained. Results: 19 patients were included, with a mean age of 12.6 years (SD ± 2.29). 58% were male. 80% of the patients presented protective immunoglobulin G antibodies against HAV 7-year post-vaccination. The antibody concentration was found to be between 13 and 80 mIU/mL (median of 80 mIU/mL). 52% showed some degree of immunosuppression. There was no statistically significant relationship between the presence of seroprotection and viral load, treatment failure, immunological category, and malnutrition. Twelve patients presented with antiretroviral treatment failure, and in 33% of them, the antibodies did not offer satisfactory seroprotection. Conclusion: 7-year post-vaccination, 80% of HIV-infected children maintain seroprotection titers against HAV.

RESUMEN Introducción: La COVID-19 se convirtió en un problema de salud multidimensional, que no solo culminó con el diagnóstico y tratamiento de los pacientes y lograr un control de la pandemia, sino fue un poco más allá con consecuencias a nivel orgánico y funcional en los individuos una vez culminada la fase aguda de la enfermedad quedando definidas determinadas condiciones postCOVID-19 que pudieran limitar la aptitud de los trabajadores para la actividad específica que realiza. Objetivo: Identificar características clínico-epidemiológicas y aptitud para el trabajo en trabajadores convalecientes de COVID-19. Métodos: Se realizó un estudio descriptivo transversal de trabajadores de La Habana atendidos en la consulta multidisciplinaria del Instituto Nacional de Salud de los Trabajadores para convalecientes de COVID-19 durante el periodo de mayo/2021 a septiembre/2022.La población estuvo conformada por 222 trabajadores de diferentes sectores ocupacionales. Resultados: Predominaron los sectores ocupacionales: salud (70,7 %); construcción (8,6 %) y gastronomía y comercio (8,1 %); la forma clínica enfermedad no complicada (mínimamente sintomática) (57,2 %). Los síntomas que persistieron fueron disnea (33,8 %), debilidad en miembros inferiores (31,1 %) artralgias (23 %). La hipertensión arterial (63,5 %), la obesidad (29,1 %) y el asma bronquial (20,2 %) prevalecieron como principales comorbilidades. Aptos para el puesto trabajo, la totalidad de los trabajadores. Conclusiones: La persistencia de los síntomas postCOVID-19 es frecuente. El sexo femenino, la edad de 50 a 59 años y la hipertensión arterial son factores asociados. Se aporta información acertada sobre trabajadores de diferentes sectores ocupacionales en Cuba que padecieron COVID-19 persistente de lo cual no existen antecedentes en el país.

ABSTRACT Introduction: COVID-19 became a multidimensional health problem, which not only culminated in the diagnosis and treatment of patients and achieving control of the pandemic, but went a little further with consequences at an organic and functional level in the patients. individuals once the acute phase of the disease has ended, defining certain post-COVID-19 conditions that could limit the workers' aptitude for the specific activity they carry out. Objective: Identify clinical-epidemiological characteristics and fitness for work in workers convalescing from COVID-19. Material and Methods: A cross-sectional descriptive study was carried out on workers from Havana treated in the multidisciplinary consultation of the National Institute of Workers' Health for convalescents from COVID-19 during the period from May 2021 to September 2022. The population was made up of 222 workers from different occupational sectors. Results: The occupational sectors predominated: health (70.7%); construction (8.6%) and gastronomy and commerce (8.1%); the clinical form uncomplicated disease (minimally symptomatic) (57.2%). The symptoms that persisted were dyspnea (33.8%), weakness in lower limbs (31.1%), and arthralgia (23%). High blood pressure (63.5%), obesity (29.1% and bronchial asthma (20.2%) prevailed as the main comorbidities. All workers were suitable for the job. Conclusions: The persistence of post-COVID-19 symptoms is common. Female sex, age from 50 to 59 years and high blood pressure are associated factors. Accurate information is provided about workers from different occupational sectors in Cuba who suffered from persistent COVID-19, for which there is no history in the country.

ABSTRACT Alterations in blood cell counts are the most prominent and recurrent clinical findings among patients suffering from both acute and chronic liver disease. These changes are an important marker of liver failure and often play a key role in the evaluation and management of these patients. Together with the prolongation of coagulation tests, thrombocytopenia is the most common disorder among these individuals. This condition, as well as leukopenia, is largely attributable to hypersplenism, a disorder in which the spleen retains and destroys blood cells, including platelets. However, when the platelet count drops below 10x103/µl, it is essential to consider other causes, such as autoimmune factors that may be contributing to the development of thrombocytopenia. Anemia, defined as a decrease in red blood cell count or hemoglobin levels, is another common characteristic of liver disease. Although in most cases macrocytic anemia occurs, in some situations it can be secondary to hemolytic events, as observed in Zieve’s syndrome. This wide range of manifestations of anemia among liver patients highlights the complex interaction between liver and blood components. Despite advances in understanding the underlying causes of these cytopenias, treatment options remain limited. Therapeutic options generally focus on the transfusion of blood products to compensate for deficiencies in cell counts or on the use of thrombopoietin (TPO) analogues to temporarily stimulate platelet production in the bone marrow. However, these treatments tend to address the symptoms rather than the root causes of hematologic disorders in liver disease. The persistence and worsening of these disorders may serve as early indicators of the progression of liver failure. The complicated relationship between liver and hematological homeostasis remains the subject of research. A deeper understanding of these mechanisms could potentially open the door toward more targeted and effective therapeutic approaches to address cytopenias in the context of liver disease.

RESUMEN Las alteraciones en los recuentos celulares sanguíneos representan los hallazgos clínicos más notorios y recurrentes en pacientes que padecen enfermedad hepática, tanto aguda como crónica. Estos cambios constituyen un marcador importante de la disfunción hepática y, a menudo, desempeñan un papel crucial en la evaluación y manejo de estos pacientes. En conjunto con el alargamiento de las pruebas de coagulación, la trombocitopenia es la irregularidad más prevalente en estos individuos. Esta condición, así como las leucopenias, se le atribuye en gran medida al hiperesplenismo, una alteración en la que el bazo retiene y destruye las células sanguíneas, incluidas las plaquetas. Sin embargo, cuando el conteo plaquetario desciende por debajo de 10 x 103/µl, es fundamental considerar otras causas, como factores autoinmunitarios que pueden estar contribuyendo con la trombocitopenia. La anemia, definida como una disminución en el número de glóbulos rojos o en los niveles de hemoglobina, es otra característica constante que acompaña a la enfermedad hepática. Aunque en la mayoría de los casos la anemia es macrocítica, en algunas situaciones puede ser secundaria a eventos hemolíticos, como lo observado en el síndrome de Zieve. Esta diversidad en las manifestaciones de la anemia en pacientes hepáticos subraya la complejidad de las interacciones entre el hígado y los componentes sanguíneos. A pesar de los avances en la comprensión de las causas subyacentes de estas citopenias, las opciones del tratamiento siguen siendo limitadas. Generalmente, las opciones terapéuticas se enfocan en la administración de transfusiones de hemocomponentes para compensar las deficiencias en los recuentos celulares o en el uso de análogos de trombopoyetina (TPO) para estimular temporalmente la producción de las plaquetas en la medula ósea. No obstante, estos tratamientos tienden a abordar los síntomas más que las causas fundamentales de las alteraciones hematológicas en la enfermedad hepática. La persistencia y el empeoramiento de estas alteraciones pueden servir como indicadores tempranos de la progresión de la disfunción hepática. La relación intrincada entre el hígado y la homeostasis hematológica continúa siendo objeto de investigación, la compresión más profunda de estos mecanismos podría abrir potencialmente la puerta hacia enfoques terapéuticos más específicos y efectivos para abordar las citopenias en el contexto de la enfermedad hepática.

Abstract Objective: To evaluate the clinical-surgical results of the tubular vs. mini-open approach in lumbar discoidectomy. The tubular approach promises to reduce the number of rest days and an earlier return to daily activities and work. Method: A case-control study of patients operated on for disc herniation using tubular surgery (case) and mini-open (control) was carried out. The variables investigated were as follow: radicular and lumbar pain, sex, age, failure in conservative treatment, single-level lumbar hernia, surgical time, bleeding, length of hospital stay, persistence of symptoms, complications, occupational activity, and reintegration into everyday activities. Results: Through 100 surgeries performed, two groups were created, tubular and mini-open, with 50 patients each, with L4-L5 or L5-S1 disc herniation, respectively. The most affected level was L4-L5 (69%). Of the total cases, a significant improvement was found (p < 0.05) at 15 postoperative days in the VAS and ODI scale in the tubular group with respect to mini-open. Complications such as surgical wound infection, durotomy, and persistent pain occurred. Conclusions: The tubular approach is a safe and effective option for herniated discs of the lumbar segment, and reduces surgical times, bleeding, and the time of reinsertion to daily activities of the patient.

Resumen Objetivo: Evaluar los resultados clínico-quirúrgicos del abordaje tipo tubular en comparación con el mini-open en la discoidectomía lumbar. El abordaje tubular promete reducir el número de días de reposo y una reincorporación más temprana a las actividades diarias y laborales. Método: Se realizó un estudio de casos y controles de pacientes operados por hernia discal mediante cirugía tubular (casos) o mini-open (controles). Las variables investigadas fueron: dolor radicular y lumbar, sexo, edad, falla en el tratamiento conservador, hernia lumbar de un solo nivel, tiempo quirúrgico, sangrado, tiempo de estancia hospitalaria, persistencia de síntomas, complicaciones, tipo de actividad ocupacional y reinserción a las actividades cotidianas. Resultados: Se realizaron 100 cirugías y se crearon dos grupos, tubular y mini-open, con 50 pacientes cada uno, con hernia discal de L4-L5 o L5-S1, respectivamente. El nivel más afectado fue L4-L5 (69%). Del total de los casos, se encontró mejoría significativa (p < 0.05) a los 15 días posquirúrgicos en la escala EVA y ODI en el grupo tubular con respecto al mini-open. Ocurrieron complicaciones como infección de herida quirúrgica, durotomía y dolor persistente. Conclusiones: El abordaje tubular es una opción segura y efectiva para hernias discales del segmento lumbar, y reduce los tiempos quirúrgicos, el sangrado y el tiempo de reinserción a las actividades cotidianas del paciente.

Abstract Background: Long COVID is defined as the persistence of COVID-19 symptoms four weeks after having undergone acute infection, according to the most recent CDC definition. It is estimated that there are 65 million people affected by this entity, although other figures speak of 200 million. Objective: To characterize the population affected by long COVID in Mexico. Material and methods: Patients older than 18 years who agreed to answer an online survey and who met the criteria for long COVID were included. Results: Data from 203 subjects were included, with 138 (68.0%) being found to be females, and average age to be 41.8 years; 29.6% had severe disease, and 70.4%, mild to moderate disease; 89.7% had received prior COVID-19 vaccination: 6.9% had received one dose; 31.5%, two doses; and 51.2%, three or more doses. The main risk factors were diabetes, overweight or obesity, and hypertension. The most commonly reported symptom was fatigue, followed by other neuropsychiatric manifestations. Conclusion: It is important for the population affected by long COVID to be characterized in order to generate diagnostic and treatment protocols.

Resumen Antecedentes: El COVID persistente se define como la persistencia de síntomas de COVID-19 después de cuatro semanas de cursar con un cuadro agudo, según la definición más reciente de los Centers for Disease Control and Prevention. Se estima que existen 65 millones de personas afectadas por esta entidad, aunque algunos reportes indican 200 millones. Objetivo: Caracterizar a la población afectada por COVID persistente en México. Material y métodos: Se incluyeron pacientes mayores de 18 años que consintieron responder a una encuesta en línea y que cumplían los criterios de COVID persistente. Resultados: Se incluyeron los datos de 203 sujetos. Se identificó que 138 (68.0 %) contestaron ser del sexo femenino, con una media de edad de 41.8 años; 29.6 % presentó enfermedad grave y 70.4 %, enfermedad leve a moderada; 89.7 % había recibido vacunas previas para COVID-19: 6.9 %, una dosis; 31.5 %, dos dosis; y 51.2 %, tres o más dosis. Los principales factores de riesgo fueron diabetes, sobrepeso u obesidad e hipertensión arterial sistémica. El principal síntoma reportado fue fatiga, seguido de otras manifestaciones neuropsiquiátricas. Conclusión: Es importante caracterizar a la población para generar protocolos de diagnóstico y tratamiento.

Resumo A hidradenite supurativa é uma doença inflamatória crónica associada a múltiplas comorbilidades e a sua associação com doenças linfoproliferativas tem sido, recentemente, um tema de debate. No entanto, é controverso se esse risco pode ser atribuído à própria doença ou se tem relação com o tratamento imunossupressor. Descrevemos o caso de um doente com hidradenite supurativa perianal grave tratada com metotrexato e infliximab, cuja exacerbação com persistência de sintomas graves refratários ao tratamento adequado levou ao diagnóstico de linfoma não-Hodgkin difuso de grandes células B. Optou-se pela realização de colostomia para melhoria da sépsis perianal e início de imunoquimioterapia.

Abstract Hidradenitis suppurativa is a chronic inflammatory disease associated with multiple comorbidities, and its association with lymphoma has recently been a topic of debate. However, it is still controversial whether this risk can be attributed to the disease itself or whether it has any relationship with immunosuppressive treatment. Here, we describe the case of a patient with severe perianal hidradenitis suppurativa treated with methotrexate and infliximab, whose exacerbation with persistence of severe symptoms refractory to adequate treatment led to the diagnosis of diffuse large non-Hodgkin B-cell lymphoma. It was decided to perform a colostomy to improve perianal sepsis, and immunochemotherapy was proposed.

ABSTRACT: Persistent organic pollutants (POPs) represent a significant environmental problem due to their toxicity, with a high capacity to persist in the environment, resistance to conventional degradation methods, the ability to accumulate in living organisms and their magnification in food chains or food. In this review article, the impacts on health and environmental components are examined. Strategies and measures for control, mitigation and/or minimization of POPs are also addressed. Agricultural and industrial activities, inadequate final disposal of solid waste and lack of wastewater treatment are identified as the main sources of POP emissions. In addition, innovative and promising technologies are analyzed, such as nanotechnology, bioremediation, rhizoremediation, biochar, chromatography techniques, ultrasound, among others, for the adequate treatment of POPs. The review highlights both the advantages and limitations of these technologies, pointing out areas that still require developments to achieve effective treatments. More economical and ecological alternatives are also mentioned to counteract the impacts of POPs.

RESUMEN: Los contaminantes orgánicos persistentes (COP) representan un problema ambiental significativo debido a su toxicidad, con una alta capacidad para persistir en el entorno, resistencia a los métodos de degradación convencionales, la capacidad de acumulación en organismos vivos y su magnificación en las cadenas tróficas o alimentarias. En este artículo de revisión, se examinan los impactos en la salud y en los componentes medio ambientales. También se abordan las estrategias y medidas de control, mitigación y/o minimización de los COP. Se identifica a las actividades agrícolas, industriales, la inadecuada disposición final de los residuos sólidos y la falta de tratamiento de las aguas residuales como las principales fuentes de emisión de COP. Además, se analizan tecnologías innovadoras y prometedoras, como la nanotecnología, biorremediación, rizorremediación, biocarbón, técnicas de cromatografía, ultrasonido, entre otras, para el tratamiento adecuado de los COP. La revisión destaca tanto las ventajas como las limitaciones de estas tecnologías, señalando áreas que aún requieren desarrollos para lograr tratamientos eficaces. También se mencionan alternativas más económicas y ecológicas, para contrarrestar los impactos de los COP.

Resumo A contaminação ambiental com metais pesados é uma ameaça aos organismos devido à sua toxicidade, persistência e bioacumulação nas cadeias alimentares. O estudo teve como objetivo avaliar o efeito do Cd sobre o nível de Ca em ossos de peixes de água doce Channa gachua. Quarenta e dois indivíduos de peixes foram mantidos em seis aquários; marcado aq. 0, 1, 2, 3, 4 e 5 no laboratório para tratamento. Aq. 0 foi o grupo controle e aq. 1, 2, 3, 4, 5 foram experimentais com solução de tratamento de Cd 0, 0,1 ppm, 0,5 ppm, 1 ppm, 2,5 ppm e 5 ppm respectivamente por três meses. Após a exposição, o tecido ósseo foi examinado quanto ao acúmulo de Cd e concentração de Ca. O maior acúmulo de Cd foi registrado em aq. 5 com média de 46,86 ± 0,46 mgkg-1 e o menor no grupo controle com média de 0,61 ± 0,06 mgkg-1. A ordem de bioacumulação de Cd nos ossos foi aq. 5 > aq. 4 > aq. 3 > aq. 2 > aq. 1 > aq. 0. A concentração mais alta de Ca foi observada em aq. 0 (grupo controle) média de 7.888,06 ± 4.827,22 mgkg-1 e a mais baixa foi de 1.132,36 ± 203,73 mgkg-1 em aq. 5 (a 5,0 ppm). Geralmente um padrão de diminuição do nível de Ca foi observado com cada aumento da bioacumulação de Cd aq. 0 > aq. 1 > aq. 2 > aq. 3 > aq. 4 > aq. 5. O estudo atual indicou que o acúmulo de Cd tem efeito substancial no nível de Ca nos ossos e, portanto, no sistema esquelético. Regras estritas devem ser implementadas pelo governo para controlar a poluição por metais e a exploração da biota.

Abstract Environmental contamination with heavy metals is a threat to the organisms due to their toxicity, persistence and bioaccumulation in food chains. The study was aimed to assess cadmium (Cd) effect on calcium (Ca) level in bones of a freshwater fish Channa gachua. 42 fish individuals were kept into six (6) aquaria; labelled aq.0, 1, 2, 3,4 and 5 in the laboratory for treatment. Aq.0 was control group and aq.1, 2,3,4,5 were experimental with treatment solution of Cd 0, 0.1ppm, 0.5ppm, 1ppm, 2.5ppm and 5ppm respectively for three months. After exposure, bones tissue were examined for Cd accumulation and Ca concentration. Highest accumulation of Cd were recorded in aq.5 mean 46.86 ± 0.46 mgkg-1 .and lowest in the control group with mean 0.61 ± 0.06 mgkg-1. The order of Cd bioaccumulation in bones were aq.5 > aq.4 >aq.3 > aq.2 > aq.1 > aq.0. Highest concentration of Ca were noted in aq.0 (Control group) mean 7888.06 ± 4827.22 mgkg-1 and lowest were 1132.36 ± 203.73 mgkg-1 in aq.5 (at 5.0 ppm). Generally a pattern of decreasing Ca level were observed with each rise of Cd bioaccumulation aq.0 > aq.1 > aq.2 > aq.3 > aq.4 > aq.5. Current study indicated that Cd accumulation have substantial effect on Ca level in bones and hence on skeleton system. Strict rules must be implemented by government to control metals pollution and exploitations of biota.

ABSTRACT Introduction: Understanding the intricate dynamics between different waves of the COVID-19 pandemic and the corresponding variations in clinical outcomes is essential for informed public health decision-making. Comprehensive insights into these fluctuations can guide resource allocation, healthcare policies, and the development of effective interventions. This study aimed to compare the characteristics and clinical outcomes of COVID-19 at peak transmission points by including all patients attended during the first four pandemic waves in a referral center in Colombia. Material and methods: In a prospective observational study of 2733 patients, clinical and demographic data were extracted from the Fundacion Valle de Lili's COVID-19 Registry, focusing on ICU admission, Invasive Mechanical Ventilation (IMV), length of hospital stay, and mortality. Results: Our analysis unveiled substantial shifts in patient care patterns. Notably, the proportion of patients receiving glucocorticoid therapy and experiencing secondary infections exhibited a pronounced decrease across waves (p < 0.001). Remarkably, there was a significant reduction in ICU admissions (62.83% vs. 51.23% vs. 58.23% vs. 46.70 %, p < 0.001), Invasive Mechanical Ventilation (IMV) usage (39.25% vs. 32.22% vs. 31.22% vs. 21.55 %, p < 0.001), and Length of Hospital Stay (LOS) (9 vs. 8 vs. 8 vs. 8 days, p < 0.001) over the successive waves. Surprisingly, hospital mortality remained stable at approximately 18-20 % (p > 0.05). Notably, vaccination coverage with one or more doses surged from 0 % during the initial waves to 66.71 % in the fourth wave. Conclusions: Our findings emphasize the critical importance of adapting healthcare strategies to the evolving dynamics of the pandemic. The reduction in ICU admissions, IMV utilization, and LOS, coupled with the rise in vaccination rates, underscores the adaptability of healthcare systems. Hospital mortality's persistence may warrant further exploration of treatment strategies. These insights can inform public health responses, helping policymakers allocate resources effectively and tailor interventions to specific phases of the pandemic. Introduction COVID19 COVID 19 COVID-1 decisionmaking. decisionmaking decision making. making decision-making allocation policies Colombia methods 273 Lilis Lili s Registry admission IMV, , stay Results patterns Notably 0.001. 0001 0.001 . 001 Remarkably 62.83% 6283 62 83 (62.83 vs 5123 51 23 51.23 5823 58 58.23 4670 46 70 46.7 0.001, (IMV 39.25% 3925 39 25 (39.25 3222 32 22 32.22 3122 31 31.22 2155 21 55 21.5 LOS (LOS 9 ( days Surprisingly 1820 18 20 18-2 0.05. 005 0.05 05 0.05) 6671 66 71 66.7 wave Conclusions utilization rates systems mortalitys responses COVID1 1 COVID- 27 000 0.00 00 62.83 628 6 (62.8 512 5 2 51.2 582 58.2 467 4 7 46. 39.25 392 3 (39.2 322 32.2 312 31.2 215 21. 182 18- 0.0 667 66. 62.8 (62. 51. 58. 39.2 (39. 32. 31. 0. 62. (62 39. (39 (6 (3

ABSTRACT Background: The treatment of chronic pancreatitis does not consistently solve intestinal abnormalities, and despite the implementation of various therapeutic measures, patients often continue to experience persistent diarrhea. Therefore, it is imperative to recognize that diarrhea may stem from factors beyond pancreatic insufficiency, and intestinal inflammation emerges as a potential contributing factor. Objective: The aim of this study was to assess fecal lactoferrin and calprotectin levels as indicators of intestinal inflammation in patients with chronic pancreatitis experiencing persistent diarrhea. Methods: In this study, 23 male patients with chronic pancreatitis primarily attributed to alcohol consumption and presenting with diarrhea (classified as Bristol stool scale type 6 or 7), underwent a comprehensive evaluation of their clinical and nutritional status. Fecal lactoferrin and calprotectin levels were measured utilizing immunoassay techniques. Results: The average age of the participants was 54.8 years, 43.5% had diabetes, and 73.9% were smokers. Despite receiving enzyme replacement therapy and refraining from alcohol for over 4 years, all participants exhibited persistent diarrhea, accompanied by elevated calprotectin and lactoferrin levels indicative of ongoing intestinal inflammation. Conclusion: The findings of this study underscore that intestinal inflammation, as evidenced by elevated fecal biomarkers calprotectin and lactoferrin, may contribute to explaining the persistence of diarrhea in patients with chronic pancreatitis. Background abnormalities measures Therefore insufficiency factor Objective Methods 2 classified 7, 7 , 7) status techniques Results 548 54 8 54. years 435 43 5 43.5 diabetes 739 73 9 73.9 smokers Conclusion 43. 73.

RESUMO Contexto: O tratamento da pancreatite crônica não resolve de forma consistente as anomalias intestinais e, apesar da implementação de várias medidas terapêuticas, os pacientes muitas vezes continuam a apresentar diarreia persistente. Portanto, é imperativo reconhecer que a diarreia pode resultar de fatores além da insuficiência pancreática, e a inflamação intestinal surge como um potencial fator contribuinte. Objetivo: O objetivo deste estudo foi avaliar os níveis fecais de lactoferrina e calprotectina como indicadores de inflamação intestinal em pacientes com pancreatite crônica com diarreia persistente. Métodos: Neste estudo, 23 pacientes do sexo masculino com pancreatite crônica atribuída principalmente ao consumo de álcool e apresentando diarreia (classificada na escala de fezes de Bristol tipo 6 ou 7), foram submetidos a uma avaliação abrangente de seu estado clínico e nutricional. Os níveis fecais de lactoferrina e calprotectina foram medidos utilizando técnicas de imunoensaio. Resultados: A idade média dos participantes foi de 54,8 anos, 43,5% tinham diabetes e 73,9% eram fumantes. Apesar de receber terapia de reposição enzimática e abster-se de álcool por mais de 4 anos, todos os participantes apresentaram diarreia persistente, acompanhada por níveis elevados de calprotectina e lactoferrina, indicativos de inflamação intestinal contínua. Conclusão: Os achados deste estudo ressaltam que a inflamação intestinal, evidenciada pelos biomarcadores fecais elevados calprotectina e lactoferrina, pode contribuir para explicar a persistência da diarreia em pacientes com pancreatite crônica. Contexto terapêuticas persistente Portanto pancreática contribuinte Objetivo Métodos 2 classificada 7, 7 , 7) nutricional imunoensaio Resultados 548 54 8 54, anos 435 43 5 43,5 739 73 9 73,9 fumantes absterse abster se contínua Conclusão 43, 73,

ABSTRACT Introduction Instruments to manage adverse effects of endocrine therapy with Aromatase inhibitors (AI) may improve adherence and persistence to treatment and Health-Related Quality of Life (HRQL). The 31-item Cervantes Scale (CS-31) is an HRQL questionnaire with particularities of the perimenopausal and postmenopausal period that could be an appropriate instrument to assess HRQL in Breast Cancer (BC) survivors. Objective This study aimed to perform additional validation of the CS-31 for BC survivors undergoing adjuvant endocrine therapy. Methods This prospective study was performed at three time points named T0, T1, and T2: initial, intermediate, and final follow-up period, respectively, totaling 24 months of follow-up. At each time point, the participants completed the CS-31, Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), and Hospital Anxiety and Depression Scale (HADS). The internal consistency, construct validity, responsiveness analyses, and known-group validity of CS-31 were evaluated. Results This study included 89 postmenopausal women diagnosed with hormone receptor-positive early BC in adjuvant endocrine therapy with AI. The internal consistency was good (Cronbach's alpha = 0.89). Construct validity received a positive rating, with 100% of results consistent with prior hypotheses. A prospective improvement in HRQL was identified for the CS-31 Global Score and FACIT-F Total Score and for most of their domains. Furthermore, women with anxiety and depression by HADS presented worse HRQL by CS-31. Conclusion The authors identified that the CS-31 seems to be appropriate for use in oncology medical routine and may help to monitor adverse effects and HRQL of BC survivors during adjuvant endocrine therapy. AI (AI HealthRelated Health Related HRQL. . (HRQL) 31item item 31 CS31 CS (CS-31 (BC CS-3 T0 T T1 T2 initial intermediate followup follow up respectively 2 followup. up. point CS31, 31, FACITF, FACITF FACIT F , (FACIT-F) HADS. (HADS) analyses knowngroup known group evaluated 8 receptorpositive receptor Cronbachs Cronbach s 0.89. 089 0.89 0 0.89) rating 100 hypotheses domains Furthermore CS31. 31. (HRQL 3 CS3 (CS-3 CS- (FACIT-F (HADS 08 0.8 10 (CS- 0. 1 (CS

ABSTRACT Background: Monoclonal antibodies have proven efficacy in the management of several conditions and infliximab (IFX) is one of the most important drugs of the class. Some recent data have shown low rates of both persistence and adherence to several available biologics. Objective: The objective of this study was to describe adherence and persistence rate to IFX treatment and also persistence in the patient support program (PSP), among patients diagnosed with inflammatory bowel diseases (IBD) or rheumatic diseases (RD) enrolled in the program of a large pharmaceutical company in Brazil. Methods: Retrospective observational analysis using the PSP database. IBD or RD patients using IFX enrolled on the PSP database between September 2015 and August 2019 were retrospectively evaluated to identify the persistence rate and adherence and followed up until March 1, 2020. Patients were excluded if treatment start date was prior to program entry; first infusion prior to September 1st, 2015 or after August 31st, 2019; the patients did not started treatment; and patients with “OTHERS” in “Indication” field. Persistence was assessed considering both persistence in the program (“PSP persistence”) and persistence on IFX in the PSP (“IFX persistence in the PSP”). PSP persistence was defined as the proportion of patients remaining in the program at 6, 12, 24, 36 and 48 months after initiating IFX. To determine IFX persistence in the PSP, censoring was defined at the time the patient left the program, died, or was lost to follow-up. Adherence to treatment was measured by medication possession ratio ((MPR) - All days supply / elapsed days from first prescription to last day of medication possession)). Descriptive statistics were initially used. Kaplan-Meier curve, the median time estimated by the survival function, Cox regression model, and restricted mean survival time (RMST) were used to evaluate the treatment persistence time at 24 months and the logistic regression model was performed aiming to identify variables associated with adherence (MPR ≥80%). Results: A total of 10,233 patients were analyzed, 5,826 (56.9%) with the diagnosis of RD and 4,407 (43.1%) of IBD. At the end of the follow-up (median 9.1 months from PSP entry to the last infusion), persistence in the PSP was 65.6%, 48.2%, 31.0%, 20.7% and 13.1% at 6, 12, 24, 36 and 48 months, respectively. Considering persistence on IFX in the PSP, estimates were 93.7%, 87.8%, 77.0%, 62.4% and 53.0% at 6, 12, 24, 36 and 48 months, respectively. Variables associated with the risk of non-persistence were gender, country region and diagnosis of rheumatoid arthritis and ankylosing spondylitis. Median MPR was 94.2%, while the percentage of patients with MPR ≥80% was 91.0%. Variables associated with MPR≥80% were country region and diagnosis of Crohn’s disease. Conclusion: Many patients leave the program without discontinuing IFX, since the 12-month persistence were very different between program and medication estimates, while high adherence rates were observed among patients enrolled in the PSP. Data highlights the benefits of a PSP. Background (IFX class biologics Objective , (PSP) (IBD (RD Brazil Methods 201 1 2020 1st st 31st OTHERS “OTHERS Indication “Indication field persistence” . PSP”) 6 12 3 4 died followup. followup follow up. ((MPR possession. possession)) KaplanMeier Kaplan Meier curve function RMST (RMST 2 ≥80%. 80 ≥80%) Results 10233 10 233 10,23 analyzed 5826 5 826 5,82 56.9% 569 56 9 (56.9% 4407 407 4,40 43.1% 431 43 (43.1% 91 9. infusion, infusion) 656 65 65.6% 482 48.2% 310 31 0 31.0% 207 20 7 20.7 131 13 13.1 respectively 937 93 93.7% 878 87 8 87.8% 770 77 77.0% 624 62 62.4 530 53 53.0 nonpersistence non gender spondylitis 942 94 94.2% ≥80 910 91.0% MPR80 MPR≥80 Crohns Crohn s disease Conclusion 12month month (PSP 202 PSP” possession) 1023 23 10,2 582 82 5,8 56.9 (56.9 440 40 4,4 43.1 (43.1 65.6 48.2 31.0 20. 13. 93.7 87.8 77.0 62. 53. 94.2 ≥8 91.0 MPR8 MPR≥8 102 10, 58 5, 56. (56. 44 4, 43. (43. 65. 48. 31. 93. 87. 77. 94. ≥ 91. MPR≥ (56 (43 (5 (4 (

RESUMO Contexto: Os anticorpos monoclonais têm eficácia comprovada no manejo de diversas condições e o infliximabe (IFX) é um dos medicamentos mais importantes da classe. Alguns dados recentes demonstram baixas taxas de persistência e adesão a vários dos biológicos disponíveis. Objetivo: O objetivo deste estudo foi descrever a adesão e persistência ao tratamento com IFX e a persistência no programa de suporte ao paciente (PSP), entre pacientes diagnosticados com doenças inflamatórias intestinais (DII) ou doenças reumáticas (DR) inscritos no PSP de uma grande indústria farmacêutica no Brasil. Métodos: Análise observacional retrospectiva utilizando o banco de dados do PSP. Pacientes com DII ou DR usando IFX inscritos no banco de dados do PSP entre setembro de 2015 e agosto de 2019 foram avaliados retrospectivamente para identificar a taxa de persistência e adesão e acompanhados até 1º de março de 2020. Os pacientes foram excluídos se a data de início do tratamento fosse anterior à entrada no programa; primeira infusão antes de 1º de setembro de 2015 ou após 31 de agosto de 2019; o paciente não iniciou o tratamento; e pacientes com “OUTROS” no campo “indicação”. A persistência foi avaliada considerando tanto a persistência no programa (“persistência PSP”) quanto a persistência em uso de infliximabe no PSP (“persistência IFX no PSP”). A persistência no PSP foi definida como a proporção de pacientes que permaneceram no programa aos 6, 12, 24, 36 e 48 meses após o início do IFX. Para determinar a persistência do IFX no PSP, a censura foi definida quando o paciente deixou o programa, morreu ou perdeu o acompanhamento. A adesão ao tratamento foi medida pela razão de posse do medicamento (MPR)): todos os dias de fornecimento / decorridos da primeira prescrição ao último dia de posse do medicamento). A estatística descritiva foi inicialmente utilizada. A curva de Kaplan-Meier, o tempo mediano estimado pela função de sobrevida, o modelo de regressão de Cox e o tempo de sobrevida médio restrito (RMST) foram utilizados para avaliar o tempo de persistência do tratamento em 24 meses e o modelo de regressão logística foi realizado para identificar variáveis associadas à adesão (MPR ≥80%). Resultados: Foram analisados 10.233 pacientes, 5.826 (56,9%) com diagnóstico de DR e 4.407 (43,1%) de DII. Ao final do seguimento (mediana de 9,1 meses desde a entrada no PSP até a última infusão), a persistência no PSP foi de 65,6%, 48,2%, 31,0%, 20,7% e 13,1% aos 6, 12, 24, 36 e 48 meses, respectivamente. Considerando a persistência no IFX no PSP, as estimativas foram de 93,7%, 87,8%, 77,0%, 62,4% e 53,0% aos 6, 12, 24, 36 e 48 meses, respectivamente. As variáveis associadas ao risco de não persistência foram sexo, região do país e diagnóstico de artrite reumatoide e espondilite anquilosante. A mediana do MPR foi de 94,2%, enquanto o percentual de pacientes com MPR ≥80% foram de 91,0%. As variáveis associadas a MPR ≥80% foram região do país e diagnóstico de doença de Crohn. Conclusão: Muitos pacientes abandonam o programa sem interromper o IFX, pois a persistência em 12 meses foi muito diferente entre as estimativas do programa e da medicação, enquanto altas taxas de adesão foram observadas entre os pacientes inscritos no PSP. Os dados destacam os benefícios de um PSP. Contexto (IFX classe disponíveis Objetivo , (PSP) (DII (DR Brasil Métodos 201 º 2020 3 OUTROS “OUTROS indicação. indicação . “indicação” PSP” 6 4 acompanhamento (MPR)) medicamento. medicamento) utilizada KaplanMeier, KaplanMeier Kaplan Meier, Meier Kaplan-Meier RMST (RMST 2 ≥80%. 80 ≥80%) Resultados 10233 10 233 10.23 5826 5 826 5.82 56,9% 569 56 9 (56,9% 4407 407 4.40 43,1% 431 43 1 (43,1% 91 9, infusão, infusão) 656 65 65,6% 482 48,2% 310 0 31,0% 207 20 7 20,7 131 13 13,1 respectivamente 937 93 93,7% 878 87 8 87,8% 770 77 77,0% 624 62 62,4 530 53 53,0 sexo anquilosante 942 94 94,2% ≥80 910 91,0% Crohn Conclusão medicação (PSP 202 “indicação (MPR) 1023 23 10.2 582 82 5.8 56,9 (56,9 440 40 4.4 43,1 (43,1 65,6 48,2 31,0 20, 13, 93,7 87,8 77,0 62, 53, 94,2 ≥8 91,0 102 10. 58 5. 56, (56, 44 4. 43, (43, 65, 48, 31, 93, 87, 77, 94, ≥ 91, (56 (43 (5 (4 (

ABSTRACT Introduction: Head and neck cancer constitutes 3.8% of malignant neoplasms and 2.3% of cancer deaths; most common between the sixth and seventh decade of life. Laryngeal cancer is the most common non-cutaneous malignant tumor (30-40%) among head and neck tumors and the second most common cancer of the respiratory system; shows a male/female ratio of up to 10:1, which has reduced with the increase in smoking in women. Partial laryngectomy and radiotherapy are effective therapeutic methods in the treatment of patients with early laryngeal cancer, comparable in survival rates and laryngeal preservation. Objective: To evaluate the survival and follow-up of patients who received partial laryngeal surgery as the treatment of choice for tumor persistence or recurrence in two hospitals in the province of Camagüey, Cuba. Methods: The universe was made up of patients with laryngeal cancer who attended the consultations and the sample at the authors' discretion was made up of 70 patients who received surgical treatment. The following variables were considered: age, sex, topographic location of the tumor, partial surgical technique performed and survival time of the patients. Results: In the sample studied, 100% of the patients were male, between 51 and 60 years of age and with carcinomas in a glottic - supraglottic location. The most used surgical technique was subtotal laryngectomy with cricohyoidopexy without epigotoplasty. During the collection of information in consultation for the follow-up of the patients, the majority were alive. Conclusions: The treated patients were male, fifth and sixth decades of life. Glottic-supraglottic topographic location predominated and the most frequently performed surgical technique was subtotal laryngectomy with cricohyoidopexy without epigotoplasty. At the end of the study, most of the patients in both groups showed good quality of life and social integration.

RESUMEN Introducción: El cáncer de cabeza y cuello constituye el 3,8 % de las neoplasias malignas y 2,3 % de las muertes por cáncer; más frecuente entre la sexta y séptima década de la vida. El cáncer laríngeo es el tumor maligno no cutáneo más común (30-40 %) entre los tumores de cabeza y cuello y segundo cáncer más frecuente del aparato respiratorio; razón hombre/mujer de hasta 10:1, reducida con el incremento del tabaquismo en la mujer. La laringectomía parcial y la radioterapia son métodos terapéuticos efectivos en el tratamiento de pacientes con cáncer laríngeo precoz, comparables en tasas de supervivenciay conservación de la laríngea. Objetivo: Evaluar la supervivencia y seguimiento de pacientes que recibieron como tratamiento de elección por persistencia tumoral o recidiva cirugía parcial de laringe en dos hospitales de la provincia Camagüey. Métodos: El universo lo conformaron los pacientes con cáncer laríngeo que acudieron a las consultas y la muestra a criterio de los autores la integraron 70 pacientes que recibieron tratamiento quirúrgico. Se consideraron como variables: edad, sexo, localización topográfica del tumor, técnica quirúrgica parcial realizada y tiempo desupervivencia de los pacientes. Resultados: En la muestra estudiada el 100 % de los pacientes pertenecían al sexo masculino, entre 51 y 60 años de edad y con carcinomas en localización glótica-supraglótica. La técnica quirúrgica más utilizada fue la laringectomía subtotal con cricohioidopexia sin epigotoplastia. Durante la recolección de la información en consulta para el seguimiento de los enfermos, la mayoría se encontraban vivos. Conclusiones: Los pacientes tratados fueron del sexo masculino, quinta y sexta décadas de la vida. Predominó la localización topográfica glótica-supraglótica y la técnica quirúrgica realizada con mayor frecuencia la laringectomía subtotal con cricohioidopexia sin epigotoplastia. Al culminar el estudio la mayor parte de los pacientes de ambos grupos mostraronn buena calidad vida e integración social.

Introducción: El síndrome antifosfolípido es una enfermedad tromboinflamatoria autoinmune, con manifestaciones macro y microvasculares trombóticas y no trombóticas. Constituye una causa de morbilidad obstétrica, con persistencia positiva de anticuerpos antifosfolípidos. Su incidencia se estima en 2 por cada 100 000 habitantes anualmente. Su diagnóstico requiere la evaluación del perfil de anticuerpos antifosfolípidos, del fenotipo clínico y de los factores de riesgo. La anticoagulación es el tratamiento eficaz de la trombosis; sin embargo, en los episodios microvasculares y no trombóticos, resulta fundamental la inmunosupresión. Objetivo: Resumir el conocimiento científico actualizado acerca de este síndrome, desde la epidemiología, patogenia, diagnóstico, criterios de clasificación y tratamiento; en función de su reconocimiento, principalmente en la atención primaria de salud. Métodos: Se realizó una búsqueda en las bases de datos SciELO, LILACS, Google académico, Biblioteca Cochrane y Pubmed, durante los últimos 5 años. Se encontraron 82 artículos y se incluyeron 37 en el estudio, con un 97, 3% de actualización. Conclusiones: A pesar de los avances obtenidos en la patogenia, el diagnóstico, el tratamiento y los criterios de clasificación, que incluyen el livedo reticular, la trombocitopenia, las valvulopatías y la nefropatía, es necesario desarrollar herramientas para medir la actividad de la enfermedad, el pronóstico a largo plazo y perfeccionar la escala de daño orgánico. Esto en función de reducir la mortalidad y aumentar la calidad de vida en pacientes con síndrome antifosfolípido.

Introduction: antiphospholipid syndrome is an autoimmune thrombo-inflammatory disease with thrombotic and non-thrombotic macro- and microvascular manifestations. It constitutes a cause of obstetric morbidity with positive persistence of antiphospholipid antibodies. Its incidence is estimated at 2 per 100,000 inhabitants annually. Its diagnosis requires evaluation of the antiphospholipid antibody profile, clinical phenotype and risk factors. Anticoagulation is the effective treatment of thrombosis. However, immunosuppression is essential in microvascular and non-thrombotic episodes. Objective: to summarize the updated scientific knowledge on this syndrome from the epidemiology, pathogenesis, diagnosis, classification and treatment criteria based on its recognition, mainly in primary health care. Methods: a search was carried out in SciELO, LILACS, Google Scholar, Cochrane Library and Pubmed databases over the last 5 years. A number of 82 articles were found and 37 were included in the study with 97.3% updated. Conclusions: despite the advances obtained in the pathogenesis, diagnosis, treatment and classification criteria including livedo reticularis, thrombocytopenia, valvular diseases and nephropathy, it is necessary to develop tools to measure disease activity, long-term prognosis and improve the scale of organ damage. This is in order to reduce mortality and increase quality of life in patients with antiphospholipid syndrome.

Abstract Introduction and Objectives Certolizumab Pegol (CZP) is an anti-TNF agent approved in Brazil for Crohn's disease (CD). There is a lack of data in Brazil and Latin America detailing real-world experiences with CZP. The primary objective was clinical remission in weeks 26 and 54. The secondary endpoints were clinical response in weeks 26 and 54, endoscopic remission, biological switch rates, rates of CD-related surgery, persistence with treatment over time, and adverse events. Remission and clinical response were defined as HBI ≤4 and ≥3 points reduction of HBI, respectively. Endoscopic remission was defined as the complete healing of the intestinal mucosa. Methods This observational and retrospective study included patients with CD from 4 Brazilian centers who received CZP during their disease course. Results Forty-five patients were included. The median age was 42.16 years old, 53.3% had perianal involvement, 37.8% had undergone previous surgery, and 71.1% of patients were anti-TNF naïve. Clinical remission was observed in 73.2% and 62.5% of patients at weeks 26 and 54, respectively. Clinical response was observed in 14.63% and 18.75% in weeks 26 and 54, respectively. Endoscopic remission was observed in 36.4% of patients. A switch to biological therapy was performed in 57.8% of patients. Eleven patients underwent abdominal surgery; 62.25% discontinued treatment with CZP, with a median of 16 months, and 22.2% presented drug-related adverse events. Conclusions CZP in CD was associated with clinical remission and response rates compatible with international real-world case series. Most patients needed to switch to biological therapy due to inadequate disease control. (CZP antiTNF anti TNF Crohns Crohn s CD. . (CD) realworld real world 2 54 CDrelated related surgery time events ≤ 3 ≥ respectively mucosa course Fortyfive Forty five 4216 42 42.1 old 533 53 53.3 involvement 378 37 8 37.8 711 71 1 71.1 naïve 732 73 73.2 625 62 5 62.5 1463 14 63 14.63 1875 18 75 18.75 364 36 36.4 578 57 57.8 6225 25 62.25 months 222 22 22.2 drugrelated drug series control (CD 421 42. 53. 37. 7 71. 73. 6 62. 146 14.6 187 18.7 36. 57. 622 62.2 22. 14. 18.